Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus

K. M. Goode, J. John, A. S. Rigby, E. S. Kilpatrick, Stephen Atkin, T. Bragadeesh, A. L. Clark, J. G F Cleland

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Glycated haemoglobin (HbA1c) is an indicator of average blood glucose concentrations over the preceding 3 months, is simpler to perform than either a fasting glucose or glucose tolerance test and is associated with a worse prognosis in some clinical settings. However, its relationship to survival in patients with suspected heart failure has not been studied. Methods: Patients referred to a community-based heart failure clinic with suspected heart failure had a comprehensive assessment including the measurement of HbA1c. For this analysis, patients with DM or who started diabetic medication in the subsequent 12 months, which might influence HbA1c, were excluded. Findings: Of 970 non-diabetic patients referred between 2001 and 2004, the median age was 72 years (range 25 to 96 years), 56% were men, 45% had left ventricular ejection fraction (LVEF) ≤45%, and 50% had an HbA1c >6% (upper reference limit). Among patients with LVEF ≤45%, there was an abrupt increase in mortality in those with an HbA1c >6.7% (n = 68) compared with those with HbA1c ≤6.7% (n = 368) (hazard ratio (HR): 2.4, p<0.001), and this persisted after adjustment for age and comorbidity (HR 1.9, p = 0.008); respective 1-year mortalities were 26.5% and 9.4%. This increase in mortality was not seen in those with LVEF >45% (HR 1.44, p = 0.36 after adjustment). Interpretation: The abrupt increase in mortality with HbA1c may make it a useful risk stratification tool in non-diabetic patients with LVEF ≤45% which could help improve clinical management.

Original languageEnglish
Pages (from-to)917-923
Number of pages7
JournalHeart
Volume95
Issue number11
DOIs
Publication statusPublished - Jun 2009
Externally publishedYes

Fingerprint

Glycosylated Hemoglobin A
Left Ventricular Dysfunction
Diabetes Mellitus
Mortality
Stroke Volume
Heart Failure
Therapeutics
Social Adjustment
Glucose Tolerance Test
Blood Glucose
Fasting
Glucose
Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. / Goode, K. M.; John, J.; Rigby, A. S.; Kilpatrick, E. S.; Atkin, Stephen; Bragadeesh, T.; Clark, A. L.; Cleland, J. G F.

In: Heart, Vol. 95, No. 11, 06.2009, p. 917-923.

Research output: Contribution to journalArticle

Goode, K. M. ; John, J. ; Rigby, A. S. ; Kilpatrick, E. S. ; Atkin, Stephen ; Bragadeesh, T. ; Clark, A. L. ; Cleland, J. G F. / Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. In: Heart. 2009 ; Vol. 95, No. 11. pp. 917-923.
@article{751debf2844c4d03a88877d96c1c8e19,
title = "Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus",
abstract = "Background: Glycated haemoglobin (HbA1c) is an indicator of average blood glucose concentrations over the preceding 3 months, is simpler to perform than either a fasting glucose or glucose tolerance test and is associated with a worse prognosis in some clinical settings. However, its relationship to survival in patients with suspected heart failure has not been studied. Methods: Patients referred to a community-based heart failure clinic with suspected heart failure had a comprehensive assessment including the measurement of HbA1c. For this analysis, patients with DM or who started diabetic medication in the subsequent 12 months, which might influence HbA1c, were excluded. Findings: Of 970 non-diabetic patients referred between 2001 and 2004, the median age was 72 years (range 25 to 96 years), 56{\%} were men, 45{\%} had left ventricular ejection fraction (LVEF) ≤45{\%}, and 50{\%} had an HbA1c >6{\%} (upper reference limit). Among patients with LVEF ≤45{\%}, there was an abrupt increase in mortality in those with an HbA1c >6.7{\%} (n = 68) compared with those with HbA1c ≤6.7{\%} (n = 368) (hazard ratio (HR): 2.4, p<0.001), and this persisted after adjustment for age and comorbidity (HR 1.9, p = 0.008); respective 1-year mortalities were 26.5{\%} and 9.4{\%}. This increase in mortality was not seen in those with LVEF >45{\%} (HR 1.44, p = 0.36 after adjustment). Interpretation: The abrupt increase in mortality with HbA1c may make it a useful risk stratification tool in non-diabetic patients with LVEF ≤45{\%} which could help improve clinical management.",
author = "Goode, {K. M.} and J. John and Rigby, {A. S.} and Kilpatrick, {E. S.} and Stephen Atkin and T. Bragadeesh and Clark, {A. L.} and Cleland, {J. G F}",
year = "2009",
month = "6",
doi = "10.1136/hrt.2008.156646",
language = "English",
volume = "95",
pages = "917--923",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus

AU - Goode, K. M.

AU - John, J.

AU - Rigby, A. S.

AU - Kilpatrick, E. S.

AU - Atkin, Stephen

AU - Bragadeesh, T.

AU - Clark, A. L.

AU - Cleland, J. G F

PY - 2009/6

Y1 - 2009/6

N2 - Background: Glycated haemoglobin (HbA1c) is an indicator of average blood glucose concentrations over the preceding 3 months, is simpler to perform than either a fasting glucose or glucose tolerance test and is associated with a worse prognosis in some clinical settings. However, its relationship to survival in patients with suspected heart failure has not been studied. Methods: Patients referred to a community-based heart failure clinic with suspected heart failure had a comprehensive assessment including the measurement of HbA1c. For this analysis, patients with DM or who started diabetic medication in the subsequent 12 months, which might influence HbA1c, were excluded. Findings: Of 970 non-diabetic patients referred between 2001 and 2004, the median age was 72 years (range 25 to 96 years), 56% were men, 45% had left ventricular ejection fraction (LVEF) ≤45%, and 50% had an HbA1c >6% (upper reference limit). Among patients with LVEF ≤45%, there was an abrupt increase in mortality in those with an HbA1c >6.7% (n = 68) compared with those with HbA1c ≤6.7% (n = 368) (hazard ratio (HR): 2.4, p<0.001), and this persisted after adjustment for age and comorbidity (HR 1.9, p = 0.008); respective 1-year mortalities were 26.5% and 9.4%. This increase in mortality was not seen in those with LVEF >45% (HR 1.44, p = 0.36 after adjustment). Interpretation: The abrupt increase in mortality with HbA1c may make it a useful risk stratification tool in non-diabetic patients with LVEF ≤45% which could help improve clinical management.

AB - Background: Glycated haemoglobin (HbA1c) is an indicator of average blood glucose concentrations over the preceding 3 months, is simpler to perform than either a fasting glucose or glucose tolerance test and is associated with a worse prognosis in some clinical settings. However, its relationship to survival in patients with suspected heart failure has not been studied. Methods: Patients referred to a community-based heart failure clinic with suspected heart failure had a comprehensive assessment including the measurement of HbA1c. For this analysis, patients with DM or who started diabetic medication in the subsequent 12 months, which might influence HbA1c, were excluded. Findings: Of 970 non-diabetic patients referred between 2001 and 2004, the median age was 72 years (range 25 to 96 years), 56% were men, 45% had left ventricular ejection fraction (LVEF) ≤45%, and 50% had an HbA1c >6% (upper reference limit). Among patients with LVEF ≤45%, there was an abrupt increase in mortality in those with an HbA1c >6.7% (n = 68) compared with those with HbA1c ≤6.7% (n = 368) (hazard ratio (HR): 2.4, p<0.001), and this persisted after adjustment for age and comorbidity (HR 1.9, p = 0.008); respective 1-year mortalities were 26.5% and 9.4%. This increase in mortality was not seen in those with LVEF >45% (HR 1.44, p = 0.36 after adjustment). Interpretation: The abrupt increase in mortality with HbA1c may make it a useful risk stratification tool in non-diabetic patients with LVEF ≤45% which could help improve clinical management.

UR - http://www.scopus.com/inward/record.url?scp=66549122728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66549122728&partnerID=8YFLogxK

U2 - 10.1136/hrt.2008.156646

DO - 10.1136/hrt.2008.156646

M3 - Article

VL - 95

SP - 917

EP - 923

JO - Heart

JF - Heart

SN - 1355-6037

IS - 11

ER -